Parametric mapping of [ 18F]FPCIT binding in early stage Parkinson's disease: A pet study

Synapse

Volumn 45, Issue 2, 2002, Pages 125-133

  Ma, Y ^b   Dhawan, V ^a   Mentis, M ^a   Chaly, T ^a   Spetsieris, P G ^a   Eidelberg, D ^a  

^a North Shore Long Island Jewish Research Institute ^*  (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Dopamine transporter; FPCIT; Neurodegenerative disease; Statistical parametric mapping

Indexed keywords

DOPAMINE TRANSPORTER; N 3 FLUOROPROPYL 2 BETA CARBOXYMETHOXY 3 BETA (4 IODOPHENYL)NORTROPANE; NORTROPANE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; CARRIER PROTEIN; MEMBRANE PROTEIN; NERVE PROTEIN; SLC6A3 PROTEIN, HUMAN; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN MAPPING; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG PROTEIN BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PUTAMEN; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TISSUE DISTRIBUTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

AGED; BRAIN MAPPING; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NORTROPANES; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TROPANES;

EID: 0035983408     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10090     Document Type: Article

References (32)

1. Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms
2. Logistic discriminant parametric mapping: A novel method for the pixel-based differential diagnosis of Parkinson's disease
3. Correlation of Parkinson's disease severity and duration with 1231-FP-CIT SPECT striatal uptake
4. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT
5. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography
6. Performance characteristics of a whole-body PET scanner
7. Combined FDOPA and 30MFD PET studies in Parkinson's disease
8. Ageing and Parkinson's disease: Substantia nigra regional selectivity
9. Rapid detection of Parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters
10. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: Implications for the symptomatic threshold
11. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD
12. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease
13. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT
14. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET
15. Dopamine transporter imaging with fluorine-18-FPCIT and PET
16. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: Correlation with symptom severity
17. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: Disparity between postmortem and positron emission tomography studies?
18. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease
19. [18F]CFT [(18F)WIN 35,428], a radioligand to study the dopamine transporter with PET: Characterization in human subjects
20. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease
21. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease
22. 11C] beta-CIT-FP for quantitation of the dopamine transporter
23. 18F]dopa metabolism in the striatum in Parkinson's disease
24. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers
25. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [(18)F]dopa-PET study
26. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: Implications for a preclinical diagnosis
27. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients
28. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT
29. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease
30. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease
31. Dopamine transporters decrease with age
32. Comparison of two pet radioligands for imaging extrastriatal dopamine transporters in human brain